JAVELIN Merkel 200: Results of Phase II Study for Merkel Cell Carcinoma

aacr2017 has 92 videos Subscribe Here

Description: Howard L. Kaufman, MD, FACS of Rutgers Cancer Institute of New Jersey gives an overview of his current research, a phase II study which involved a newly FDA-approved drug, avelumab, in patients with merkel cell carcinoma. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.
Shared By : aacr2017
Posted on : 04/27/17
Added : 7 months ago


Nothing found.

More From aacr2017

Nothing found.